Coronavirus (COVID-19)
Learn more
Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at least 1 hour before their first meal of the day
Eligibility Criteria:
Patient not receiving systemic anti-cancer treatment is eligible if:
This study is for patients age 18 and older.
Available at: Hospital of Central Connecticut
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.